RM 1929

Drug Profile

RM 1929

Alternative Names: RM1929

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aspyrian Therapeutics
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Head and neck cancer
  • Preclinical Cancer

Most Recent Events

  • 08 Sep 2017 Efficacy and safety data from a phase I/IIa trial in Head and neck cancer (Recurrent, Second-line therapy or greater) presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 19 Jul 2017 Aspyrian Therapeutics plans a phase I trial for Head and neck cancer in Japan
  • 11 May 2017 Interim adverse events and efficacy data from a phase I trial in head and neck cancer released by Aspyrian Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top